While promising for improving drug bioavailability, Amorphous Solid Dispersions (ASDs) formulation creates challenges, in particular the risk of crystallization and stability issues. Therefore, ASDs require knowledgeable testing to ensure consistent product quality and efficacy throughout its lifetime.

Company:

View Solvias USA, Inc.'s profile

Links:

https://info.solvias.com/asd-white-paper